

Accelerating global development with an Asian oncology platform

ASLAN Pharmaceuticals is a clinical-stage oncology-focused biopharma company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe

Developing in Asia for global markets

- Strategically positioned in Asia with access to larger patient population where target cancers are prevalent
- Development platform in Asia enables acceleration of drug development and generation of data suitable for submission to regulators in US, Europe and Japan
- Few, if any, approved therapies in biliary tract cancer and gastric cancer
- Experienced global management team with deep local relationships and extensive knowledge of target diseases
- Building commercial organisation in China and planning to build in US

Quick facts

Ticker

- NASDAQ: ASLN
- TPEX: 6497

(Each US ADS equivalent to 5 TPEX common shares)

Shares outstanding

160,128,940

Market Cap

US\$251M

(11 June 2018, NASDAQ)

Cash

US\$29M (31 March 2018);

US\$42M raised in NASDAQ

IPO (May 2018)

Varlitinib (ASLAN001)

Potential to be the first targeted therapy approved for biliary tract cancer and first-line treatment for HER1/HER2 coexpressing gastric cancer

- Highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2, HER3 and HER4
- Demonstrated activity in biliary tract, gastric, breast and colorectal cancer. Two phase 2 trials completed, over 400 patients dosed
- Low levels of toxicity compared to other pan-HER inhibitors
- Competitive efficacy with 60% response rate demonstrated in second line HER2+ breast cancer
- Currently no approved targeted therapies for biliary tract cancer which affects more than 200,000 people in Asia every year
- Received Orphan Drug Designation from the US FDA for biliary tract cancer and gastric cancer
- Gastric cancer: topline global phase 2 data expected late 2018
- Biliary tract cancer: topline data from global pivotal trial (TREETOPP) expected in 2019 and from China pivotal trial (JADETREE) in late 2018

ASLAN003


Oral DHODH inhibitor with potential to be first-in-class therapy for acute myeloid leukaemia (AML)

- Potent inhibition of DHODH, binding affinity up to two orders of magnitude stronger than first generation inhibitors
- Promotes differentiation of blast cells in multiple cell lines that are unresponsive to ATRA
- Lack of toxicities associated with first generation inhibitors and other AML therapies
- Interim data from phase 2 trial in relapsed or refractory AML patients expected in second half of 2018
- Preclinical studies in triple negative breast cancer and hepatocellular carcinoma underway

ASLAN004

A fully human monoclonal antibody with a potential to be a first-in-class IL-13R α 1 inhibitor

- Potently inhibits signaling of both IL-4 and IL-13 receptors which are central to the allergic response in atopic dermatitis and asthma
- By targeting IL-13R α 1, a receptor with a narrower cellular distribution than the IL-4 receptor, it has the potential to offer both a lower dose and lower dosing frequency than current alternatives for target indications
- IND expected in Q3 2018
- Phase 1 clinical trial for ASLAN004 in asthma and severe atopic dermatitis to be initiated



Management

Dr Carl Firth
Chief Executive Officer

Dr Bertil Lindmark
Chief Medical Officer

Dr Mark McHale
Chief Operating Officer

Jeff Tomlinson
Chief Business Officer

Ben Goodger
General Counsel

Kiran Asarpota
VP Finance

Stephen Doyle
VP Commercial and GM China

Dr Chih-Yi Hsieh
VP Medical and GM Taiwan

Major partnerships



Analyst coverage

Edward Tenthoff
Piper Jaffray

Jonathan Chang
Leerink Partners

Raghuram Selvaraju
H C Wainwright & Co

Robert Hazlett
BTIG

John Chang
President Capital Management Corp

Headquarters

83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
+65 6222 4235
contact@aslanpharma.com

Investor contact

Robert Uhl
Westwicke Partners
+1 858 356 5932
robert.uhl@westwicke.com

Investor contact (Taiwan)

Michael Chiang
ASLAN Pharmaceuticals
+886 2 2758 2767
investor-taiwan@aslanpharma.com

Media contact

Emma Thompson
Spurwing Communications
+65 6340 7287
emma@spurwingcomms.com